<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007724/" ref="ordinalpos=2075&amp;ncbi_uid=6636039&amp;link_uid=PMC4007724" image-link="/pmc/articles/PMC4007724/figure/fig4/" class="imagepopup">Figure 4.  From: Activation of the ERK <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> is involved in CD151-induced angiogenic effects on the formation of CD151-integrin complexes. </a></div><br /><div class="p4l_captionBody">rAAV-CD151 transfection promotes the proliferation, migration, tube formation of HUVECs via ERK signaling pathway, but not via p38. (A) MTT assays showing effects of inhibitors of ERK (PD98059, 20 μmol/L), and p38 inhibitor (SB203580, 20 μmol/L) on CD151-induced HUVECs proliferation. (B) Transwell Boyden chamber assays showing effects of inhibitors of ERK (PD98059, 20 μmol/L) and p38 inhibitor (SB203580, 20 μmol/L) on CD151 enhancement of HUVECs migration. (C) The effects of inhibitors of ERK (PD98059, 20 μmol/L), and p38 inhibitor (SB203580, 20 μmol/L) on CD151-induced HUVEC tube formation on matrigel. bP&lt;0.05 vs the control and GFP groups. dP&gt;0.05, eP&lt;0.05 vs the CD151 group without inhibitors. n=3. Mean±SEM.</div></div>